Taisho Pharmaceutical Co., Ltd.
🇯🇵Japan
An Open-label Pharmacokinetic Study of TS-172 in Patients on Hemodialysis
- First Posted Date
- 2025-02-27
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT06849778
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects
Phase 1
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT06837155
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects
Phase 1
Completed
- Conditions
- Healthy Male Subjects
- Interventions
- Drug: Triazolam and TS-172Drug: TS-172 and itraconazole
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06837142
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
Phase 3
Recruiting
- Conditions
- Hyperphosphatemia Patients on Hemodialysis
- Interventions
- Drug: TS-172 20~60 mg/dayDrug: Placebo
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06745531
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis with Phosphate Binders
Phase 2
Recruiting
- Conditions
- Hyperphosphatemia Patients on Hemodialysis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06745518
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
A Mass Balance Study of TS-172 in Healthy Adult Subjects
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT06596356
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 43
- Registration Number
- NCT05819710
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
A Food Effect Study of TS-142 in Healthy Subjects
Phase 1
Completed
- Conditions
- Effect of Food
- Interventions
- Drug: TS-142 10 mg
- First Posted Date
- 2023-02-01
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05707897
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
Phase 2
Completed
- Conditions
- Hyperphosphatemia Patients on Hemodialysis
- Interventions
- Drug: TS-172 10mg bidDrug: TS-172 30mg bidDrug: TS-172 60mg bidDrug: TS-172 20mg tidDrug: Placebo
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 326
- Registration Number
- NCT05699239
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment
Phase 1
Completed
- Conditions
- Patients with Mild or Moderate Hepatic Impairment
- Interventions
- Drug: TS-142 5 mg
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT05624944
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
© Copyright 2025. All Rights Reserved by MedPath